{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:06:59Z","timestamp":1770815219934,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To identify the contents of pills found on an intoxicated patient by ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTof).5 To highlight the potential ability that this technique can add to the clinical laboratory.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Illicit PEZ-like pills purchased from an online vendor, containing unknown substances, were investigated by UHPLC-QTof. Accurate mass and experimental data were obtained. Tentative identifications were subsequently confirmed with commercial standards.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Accurate mass data, high-energy mass spectra, elucidation software, and a review of the scientific literature enabled the tentative identification of clonazolam and flubromazolam in the PEZ-like pills. On the basis of these tentative identifications, commercial standards were purchased to confirm the initial findings. On subsequent reinterrogation of the data, flubromazolam was identified in the urine specimen of the patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Utilizing high-resolution mass data, 2 novel benzodiazepines were tentatively identified by reinterrogation of a routine analysis for drugs of abuse. Use of UHPLC-QTof in a clinical toxicology laboratory provides additional capabilities to explain and potentially improve treatment of patients presenting to the emergency department with symptoms possibly due to toxic substance ingestion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/jalm.2017.025387","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T23:05:25Z","timestamp":1532387125000},"page":"48-55","source":"Crossref","is-referenced-by-count":17,"title":["Novel Benzodiazepines (Clonazolam and Flubromazolam) Identified in Candy-Like Pills"],"prefix":"10.1093","volume":"3","author":[{"given":"Jeffrey D","family":"Pope","sequence":"first","affiliation":[{"name":"Clinical Biochemistry, Alfred Health, Commercial Road, Melbourne, Australia"},{"name":"Department of Forensic Medicine, Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Weng Choy","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, Monash Health, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf H","family":"Drummer","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine, Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans G","family":"Schneider","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, Alfred Health, Commercial Road, Melbourne, Australia"},{"name":"Central Clinical School, Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,1]]},"reference":[{"key":"2022020118312064400_B1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jat\/bkt071","article-title":"Drug screening in medical examiner casework by high-resolution mass spectrometry (UPLC-MSE-TOF)","volume":"37","author":"Rosano","year":"2013","journal-title":"J Anal Toxicol"},{"key":"2022020118312064400_B2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/FTD.0000000000000417","article-title":"Challenges for detecting valproic acid in a non-targeted urine drug screening method","volume":"39","author":"Pope","year":"2017","journal-title":"Ther Drug Monit"},{"key":"2022020118312064400_B3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11419-015-0277-6","article-title":"Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites","volume":"33","author":"Huppertz","year":"2015","journal-title":"Forensic Toxicol"},{"key":"2022020118312064400_B4","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00216-016-9439-6","article-title":"Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes","volume":"408","author":"Meyer","year":"2016","journal-title":"Anal Bioanal Chem"},{"key":"2022020118312064400_B5","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2243","article-title":"Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Test Anal"},{"key":"2022020118312064400_B6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/dta.2146","article-title":"In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples","volume":"9","author":"Noble","year":"2017","journal-title":"Drug Test Anal"},{"key":"2022020118312064400_B7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.forsciint.2016.10.021","article-title":"Looking at flubromazolam metabolism from four different angles: metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry","volume":"274","author":"Wohlfarth","year":"2017","journal-title":"Forensic Sci Int"},{"key":"2022020118312064400_B8","unstructured":"UNODC. United Nations Office on Drugs and Crime, World Drug Report 2016 Available from: http:\/\/www.unodc.org\/doc\/wdr2016\/WORLD_DRUG_REPORT_2016_web.pdf. Accesed 5\/09\/2016."},{"key":"2022020118312064400_B9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","article-title":"Flubromazolam\u2014A new life-threatening designer benzodiazepine","volume":"54","author":"\u0141ukasik-G\u0142\u00eabocka","year":"2016","journal-title":"Clinical Toxicol (Phila)"},{"key":"2022020118312064400_B10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20236","article-title":"Designer benzodiazepines: a new challenge","volume":"14","author":"Moosmann","year":"2015","journal-title":"World Psychiatry"},{"key":"2022020118312064400_B11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays","volume":"9","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Test Anal"},{"key":"2022020118312064400_B12","article-title":"Urine drug screening results from The Alfred- Cannabis leads over Amphetamines","author":"Pope","year":"2017","journal-title":"Clin Biochem Rev"},{"key":"2022020118312064400_B13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jchromb.2016.08.047","article-title":"Development and application of a multi-component LC-MS\/MS method for determination of designer benzodiazepines in urine","volume":"1035","author":"Pettersson Bergstrand","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2022020118312064400_B14","unstructured":"EMCCDA. Perspectives on drugs: synthetic cannabinoids in Europe. http:\/\/www.emcdda.europa.eu\/publications\/pods\/synthetic-cannabinoids."}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/3\/1\/48\/42353917\/3_3_1_48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/3\/1\/48\/42353917\/3_3_1_48.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:44:54Z","timestamp":1643741094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/3\/1\/48\/5581314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,7,1]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1373\/jalm.2017.025387","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,7,1]]}}}